StrataCTX® as a Steroid Sparing Device
The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy/immunotherapy treatments than the current standard treatment - topical steroids - in people who are receiving treatment for CTCL, or che
| Condition(s) | CTCL |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy/immunotherapy treatments than the current standard treatment - topical steroids - in people who are receiving treatment for CTCL, or chemotherapy/immunotherapy for solid/hematologic malignancies. Subjects will have CTCL and are being treated with topical steroids, or being treated with chemotherapy/immunotherapy for another condition and have had cutaneous reactions that have warranted initiation of topical steroids. |
| Who can participate | Inclusion Criteria: * Age ≥ 18 years * Ability to sign informed consent document * Patient with a diagnosis of CTCL who have contact dermatitis to topical mechlorethamine gel * Patients with a diagnosis of CTCL who have intractable pruritis * Patients with a diagnosis of CTCL who rely heavily on topical steroids for symptomatic relief * Patients on chemo/immunotherapy with drug induced rash Exclusion Criteria: * Patients currently undergoing radiotherapy * Patients currently receiving oral steroids * Patients who are unable to apply topical medications |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Columbia University |
| Locations | New York, New York, United States |
| Start date | 2021-07-07 |
| NCT ID | NCT04087629 |
| Official listing | https://clinicaltrials.gov/study/NCT04087629 |